Genetic polymorphism of urokinase-type plasminogen activator is interacting with plasminogen activator inhibitor-1 to raise risk of cervical neoplasia

Yi Torng Tee, Po Hui Wang, Hsiu Ting Tsai, Long Yau Lin, Hung Ting Lin, Shun Fa Yang, Yi Hsien Hsieh, Tsung Ho Ying

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background and Objectives: To evaluate the impact of plasminogen activator (PA) system genes, including urokinase plasminogen activator (uPA), uPA receptor (uPAR), and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms in patients with the cervical neoplasia. Methods: In total, 336 blood samples were collected from healthy women and 136 patients with cervical neoplasia to analyze the gene polymorphisms of representative PA system genes. Results: There was no significant association between cervical neoplasia cases and gene polymorphisms of uPA, uPAR and PAI-1 genes as well as to the carcinogenesis of cervical if the cervical neoplasia cases were stratified to HSILs and invasive cancer cases. However, we found a mutual interaction between uPA/PAI-1 genes, which women carrying the uPA/PAI-1 CC/4G4G allele had a 1.70-fold higher risk (OR = 1.70; 95% CI 1.04-2.79) of cervical neoplasia compared with those carrying the CC/4G5G allele. Conclusions: Individuals with uPA/PAI-1 CC/4G5G allele were in high susceptibility for cervical neoplasia. The combined polymorphism of uPA/PAI-1 might diminish the ability of PAI-1 to inhibiting cervical cancer carcinogenesis when PAI-1 alone as the role of inhibitor.

Original languageEnglish
Pages (from-to)204-208
Number of pages5
JournalJournal of Surgical Oncology
Volume106
Issue number2
DOIs
Publication statusPublished - Aug 1 2012
Externally publishedYes

Fingerprint

Plasminogen Activator Inhibitor 1
Urokinase-Type Plasminogen Activator
Genetic Polymorphisms
Plasminogen Activators
Neoplasms
Genes
Urokinase Plasminogen Activator Receptors
Alleles
Carcinogenesis
Uterine Cervical Neoplasms

Keywords

  • cervical cancer
  • genetic polymorphism
  • PAI-1
  • uPA
  • uPAR

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Genetic polymorphism of urokinase-type plasminogen activator is interacting with plasminogen activator inhibitor-1 to raise risk of cervical neoplasia. / Tee, Yi Torng; Wang, Po Hui; Tsai, Hsiu Ting; Lin, Long Yau; Lin, Hung Ting; Yang, Shun Fa; Hsieh, Yi Hsien; Ying, Tsung Ho.

In: Journal of Surgical Oncology, Vol. 106, No. 2, 01.08.2012, p. 204-208.

Research output: Contribution to journalArticle

Tee, Yi Torng ; Wang, Po Hui ; Tsai, Hsiu Ting ; Lin, Long Yau ; Lin, Hung Ting ; Yang, Shun Fa ; Hsieh, Yi Hsien ; Ying, Tsung Ho. / Genetic polymorphism of urokinase-type plasminogen activator is interacting with plasminogen activator inhibitor-1 to raise risk of cervical neoplasia. In: Journal of Surgical Oncology. 2012 ; Vol. 106, No. 2. pp. 204-208.
@article{c0e5f57fc7b64faaa217e3f5fb62850f,
title = "Genetic polymorphism of urokinase-type plasminogen activator is interacting with plasminogen activator inhibitor-1 to raise risk of cervical neoplasia",
abstract = "Background and Objectives: To evaluate the impact of plasminogen activator (PA) system genes, including urokinase plasminogen activator (uPA), uPA receptor (uPAR), and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms in patients with the cervical neoplasia. Methods: In total, 336 blood samples were collected from healthy women and 136 patients with cervical neoplasia to analyze the gene polymorphisms of representative PA system genes. Results: There was no significant association between cervical neoplasia cases and gene polymorphisms of uPA, uPAR and PAI-1 genes as well as to the carcinogenesis of cervical if the cervical neoplasia cases were stratified to HSILs and invasive cancer cases. However, we found a mutual interaction between uPA/PAI-1 genes, which women carrying the uPA/PAI-1 CC/4G4G allele had a 1.70-fold higher risk (OR = 1.70; 95{\%} CI 1.04-2.79) of cervical neoplasia compared with those carrying the CC/4G5G allele. Conclusions: Individuals with uPA/PAI-1 CC/4G5G allele were in high susceptibility for cervical neoplasia. The combined polymorphism of uPA/PAI-1 might diminish the ability of PAI-1 to inhibiting cervical cancer carcinogenesis when PAI-1 alone as the role of inhibitor.",
keywords = "cervical cancer, genetic polymorphism, PAI-1, uPA, uPAR",
author = "Tee, {Yi Torng} and Wang, {Po Hui} and Tsai, {Hsiu Ting} and Lin, {Long Yau} and Lin, {Hung Ting} and Yang, {Shun Fa} and Hsieh, {Yi Hsien} and Ying, {Tsung Ho}",
year = "2012",
month = "8",
day = "1",
doi = "10.1002/jso.23072",
language = "English",
volume = "106",
pages = "204--208",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Genetic polymorphism of urokinase-type plasminogen activator is interacting with plasminogen activator inhibitor-1 to raise risk of cervical neoplasia

AU - Tee, Yi Torng

AU - Wang, Po Hui

AU - Tsai, Hsiu Ting

AU - Lin, Long Yau

AU - Lin, Hung Ting

AU - Yang, Shun Fa

AU - Hsieh, Yi Hsien

AU - Ying, Tsung Ho

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Background and Objectives: To evaluate the impact of plasminogen activator (PA) system genes, including urokinase plasminogen activator (uPA), uPA receptor (uPAR), and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms in patients with the cervical neoplasia. Methods: In total, 336 blood samples were collected from healthy women and 136 patients with cervical neoplasia to analyze the gene polymorphisms of representative PA system genes. Results: There was no significant association between cervical neoplasia cases and gene polymorphisms of uPA, uPAR and PAI-1 genes as well as to the carcinogenesis of cervical if the cervical neoplasia cases were stratified to HSILs and invasive cancer cases. However, we found a mutual interaction between uPA/PAI-1 genes, which women carrying the uPA/PAI-1 CC/4G4G allele had a 1.70-fold higher risk (OR = 1.70; 95% CI 1.04-2.79) of cervical neoplasia compared with those carrying the CC/4G5G allele. Conclusions: Individuals with uPA/PAI-1 CC/4G5G allele were in high susceptibility for cervical neoplasia. The combined polymorphism of uPA/PAI-1 might diminish the ability of PAI-1 to inhibiting cervical cancer carcinogenesis when PAI-1 alone as the role of inhibitor.

AB - Background and Objectives: To evaluate the impact of plasminogen activator (PA) system genes, including urokinase plasminogen activator (uPA), uPA receptor (uPAR), and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms in patients with the cervical neoplasia. Methods: In total, 336 blood samples were collected from healthy women and 136 patients with cervical neoplasia to analyze the gene polymorphisms of representative PA system genes. Results: There was no significant association between cervical neoplasia cases and gene polymorphisms of uPA, uPAR and PAI-1 genes as well as to the carcinogenesis of cervical if the cervical neoplasia cases were stratified to HSILs and invasive cancer cases. However, we found a mutual interaction between uPA/PAI-1 genes, which women carrying the uPA/PAI-1 CC/4G4G allele had a 1.70-fold higher risk (OR = 1.70; 95% CI 1.04-2.79) of cervical neoplasia compared with those carrying the CC/4G5G allele. Conclusions: Individuals with uPA/PAI-1 CC/4G5G allele were in high susceptibility for cervical neoplasia. The combined polymorphism of uPA/PAI-1 might diminish the ability of PAI-1 to inhibiting cervical cancer carcinogenesis when PAI-1 alone as the role of inhibitor.

KW - cervical cancer

KW - genetic polymorphism

KW - PAI-1

KW - uPA

KW - uPAR

UR - http://www.scopus.com/inward/record.url?scp=84863715694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863715694&partnerID=8YFLogxK

U2 - 10.1002/jso.23072

DO - 10.1002/jso.23072

M3 - Article

C2 - 22354580

AN - SCOPUS:84863715694

VL - 106

SP - 204

EP - 208

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 2

ER -